Deceleration Capacity of Heart Rate Predicts Trastuzumab‐Related Cardiotoxicity in Patients With HER2‐Positive Breast Cancer: A Prospective Observational Study

In a study of 150 patients with HER2-positive breast cancer treated with trastuzumab, investigators found that heart rate deceleration capacity (DC) was as stronger predictor of trastuzumab-associated cardiotoxicity, compared with baseline left ventricular ejection fraction or heart rate variability, and that lower DC was associated with an earlier onset of cardiotoxicity.

Journal of Clinical Pharmacy and Therapeutics